Eliminating the Plasmodium vivax malaria parasite infection remains challenging. One of the main problems is its capacity to form hypnozoites that potentially lead to recurrent infections. At present, primaquine is the only drug used for the management of hypnozoites. However, the effects of primaquine may differ from one individual to another. The aim of this work is to determine new measures to reduce P. vivax recurrence, through primaquine metabolism and host genetics. A genetic study of MAO-A, CYP2D6, CYP1A2 and CYP2C19 and their roles in primaquine metabolism was undertaken of healthy volunteers (n = 53). The elimination rate constant (K) and the metabolite-to-parent drug concentration ratio (Cm/Cp) were obtained to assess primaquine metabolism. Allelic and genotypic analysis showed that polymorphisms MAO-A (rs6323, 891G>T), CYP2D6 (rs1065852, 100C>T) and CYP2C19 (rs4244285, 19154G>A) significantly influenced primaquine metabolism. CYP1A2 (rs762551, -163C>A) did not influence primaquine metabolism. In haplotypic analysis, significant differences in K (p = 0.00) and Cm/Cp (p = 0.05) were observed between individuals with polymorphisms, GG-MAO-A (891G>T), CT-CYP2D6 (100C>T) and GG-CYP2C19 (19154G>A), and individuals with polymorphisms, TT-MAO-A (891G>T), TT-CYP2D6 (100C>T) and AA-CYP2C19 (19154G>A), as well as polymorphisms, GG-MAO-A (891G>T), TT-CYP2D6 (100C>T) and GA-CYP2C19 (19154G>A). Thus, individuals with CYP2D6 polymorphisms had slower primaquine metabolism activity. The potential significance of genetic roles in primaquine metabolism and exploration of these might help to further optimise the management of P. vivax infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00436-019-06210-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Leveraging the Aggregated Protein Dye YAT2150 for Malaria Chemotherapy.
Pharmaceutics
September 2024
Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Rosselló 149-153, 08036 Barcelona, Spain.
Article Synopsis
- YAT2150 is a new antimalarial drug that shows promise for malaria treatment and diagnosis by increasing fluorescence upon entering cells and blocking key developmental stages in malaria pathogens.
- The drug's effective uptake mechanisms and favorable pharmacokinetics make it a strong candidate for enhancing transmission-blocking strategies, especially when used in conjunction with immunoliposome encapsulation to reduce toxicity.
- YAT2150 interacts preferentially with unstructured proteins in parasites, which may lead to decreased protein aggregation, a mechanism also seen with traditional antimalarial treatments, positioning it as a potential leader in innovative malaria therapies.
Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis.
PLoS Med
September 2024
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Article Synopsis
- The study focuses on the effectiveness of 8-aminoquinolines (primaquine and tafenoquine) in curing Plasmodium vivax malaria by targeting hypnozoites, with a specific look at the role of methaemoglobin levels as a potential indicator for preventing malaria recurrence.
- The researchers conducted a systematic review of clinical studies from 2000 to 2022 and examined data from 1,747 patients treated with primaquine to analyze the relationship between methaemoglobin concentration and the time to malaria recurrence.
- Their findings suggest that higher methaemoglobin levels may correlate with a lower risk of P. vivax recurrence, indicating the potential use of methaemoglobin as
Ternary structure of Plasmodium vivaxN-myristoyltransferase with myristoyl-CoA and inhibitor IMP-0001173.
Acta Crystallogr F Struct Biol Commun
October 2024
Chemistry and Biochemistry Department, Hampton University, 200 William R. Harvey Way, Hampton, VA 23668, USA.
Article Synopsis
- Plasmodium vivax causes malaria, affecting about a third of the world's population, and primaquine treatment is unsafe for those with G6PD deficiency, which impacts a significant portion of people in endemic areas.
- The Seattle Structural Genomics Center for Infectious Disease studied PvNMT (N-myristoyltransferase) to find alternative drug targets since it's essential for P. vivax survival by facilitating protein modification.
- The newly solved crystal structure of PvNMT, showing its interaction with myristoyl-CoA and a novel inhibitor, reveals differences from human enzymes, providing insights for creating effective antimalarial drugs.
Linked-evidence modelling of qualitative G6PD testing to inform low- and intermediate-dose primaquine treatment for radical cure of Plasmodium vivax.
PLoS Negl Trop Dis
September 2024
Centre for Immunology and Infection Control, Faculty of Health, Queensland University of Technology, Brisbane, Australia.
Background: Radical cure of Plasmodium vivax infections is key to the control of vivax malaria. However, the standard doses of 8-aminoquinoline drugs used for radical cure can cause severe haemolysis in G6PD-deficient patients. The availability of near-patient G6PD tests could increase use of primaquine (PQ), however direct evidence of the impacts that G6PD testing has on downstream patient outcomes, such as haemolysis and recurrence is lacking.
View Article and Find Full Text PDFAnti-infectivity efficacy and pharmacokinetics of WHO recommended single low-dose primaquine in children with acute Plasmodium falciparum in Burkina Faso: study protocol.
Trials
September 2024
Mahidol Oxford Tropical Medicine Research Unit (MORU), 420/6 Rajvithi Road, Rajthevee, Bangkok, 10400, Thailand.
Background: Primaquine (PQ) has activity against mature P. falciparum gametocytes and proven transmission blocking efficacy (TBE) between humans and mosquitoes. WHO formerly recommended a single transmission blocking dose of 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!